¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ DPP4 (dipeptidyl peptidase-4) ¾ïÁ¦Á¦ÀÇ ½ÉÇ÷°üÁúȯ À§Çèºñ±³
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 

DPP4 (dipeptidyl peptidase-4) ¾ïÁ¦Á¦ÀÇ  ½ÉÇ÷°üÁúȯ À§Çèºñ±³

 

¿¬±¸¸ñÀû :

 

Á¦ 2Çü ´ç´¢º´ ȯÀÚ¿¡°Ô ½ÉÇ÷°üÀ§Çè°ú °ü·ÃÀÌ ÀÖ´Â 5°¡Áö Dipeptidyl Peptidase-4 inhibitors (DPP-4is) ¾ïÁ¦Á¦ÀÇ ºñ±³

 

µ¥ÀÌÅÍ Ãâó : Çѱ¹ÀÇ Nationalwide real-world data ºÐ¼®

 

Çѱ¹ÀÎ ±¹¹Î°Ç°­º¸Çè µ¥ÀÌÅÍ ºÐ¼® 2013³â 1¿ù~  2015³â 6¿ù ÀÚ·á

 

 

±×¸² ] ¿¬±¸´ë»óÀÚ ¼±º°°úÁ¤ [(CVD = cardiovascular disease; DPP-4i = dipeptidyl peptidase-4 inhibitor), Source: Korean Circ J. 2018 May;48(5):395-405.Doi: 10.4070/kcj.2017.0324]

 

 

 

Ç¥ ] HRs for CVD risk among users of different DPP-4is

BMI = body mass index; CCI = Charlson comorbidity index; CI = confidence interval; CVD = cardiovascular disease; DPP-4i = dipeptidyl peptidase-4 inhibitor; HDL = high-density lipoprotein; HR = hazard ratio; LDL = low-density lipoprotein; PY = person-years.  

*Adjusted for sex, age, duration of DPP-4i use, use of other glucose-lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), use of antiplatelet agents, hypertension, dyslipidemia, atrial fibrillation, chronic kidney disease, and microvascular complications of diabetes (retinopathy, neuropathy, or nephropathy), the CCI score, and calendar index year, †Adjusted for sex, age, duration of DPP-4i use, use of other glucose-lowering drugs (metformin, sulfonylurea, thiazolidinedione, or insulin), BMI, waist circumference, systolic blood pressure, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, fasting glucose, serum creatinine level, smoking status, family history of stroke and heart disease, the CCI score, and calendar index year. (Source: Korean Circ J. 2018 May;48(5):395-405.Doi: 10.4070/kcj.2017.0324)

 

 

°á°ú :

 

½ÃŸ±Û¸³Æ¾ »ç¿ëÀÚ (sitagliptin (n=167,157)¿Í ºñ±³ÇÏ¿© ½ÉÇ÷°ü »ç°Ç¿¡ ´ëÇÑ »ó´ëÀ§Çèµµ´Â

ºô´Ù±Û¸³Æ¾ (vildagliptin, n=67,412)¿¡¼­ 0.97 (95% CI, 0.94-1.01; p=0.163)

»è»ç±Û¸³Æ¾ (saxagliptin, n=29,479)¿¡¼­ 0.76 (95% CI, 0.71-0.81; p<0.001)

¸®³ª±Û¸³Æ¾ (linagliptin, n=220,672)¿¡¼­ 0.95 (95% CI, 0.92-0.98; p<0.001)

Á¦¹Ì±Û¸³Æ¾ (gemigliptin, n=49,607)¿¡¼­ 0.84 (95% CI, 0.80-0.88; p<0.001) ·Î º¸°íµÇ¾ú´Ù

 

 

°á·Ð

 

Çѱ¹ÀÇ nationalwide real-world data ºÐ¼®À» ÅëÇÏ¿©»è»ç±Û¸³Æ¾, ¸®³ª±Û¸³Æ¾, Àç¸Þ±Û¸³Æ¾ Ä¡·á´Â ½ÃŸ±Û¸³Æ¾ Ä¡·á¿Í ºñ±³ÇÏ¿© ½ÉÇ÷°ü »ç°ÇÀÇ ´õ ³·Àº À§Çè°ú °ü·ÃÀÌ ÀÖ´Ù.

 



 

Ãâó : Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea (2018).  Korean Circ J. 2018 May;48(5):395-405. Doi: 10.4070/kcj.2017.0324.

 

 


2018-11-20 ¿ÀÈÄ 3:54:46, Á¶È¸¼ö : 1879